Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-254-3560
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$337.28 million
Profitability
Miscellaneous
Employees518
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions
What is Pacira Biosciences' stock symbol?
Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."
How were Pacira Biosciences' earnings last quarter?
Pacira Biosciences Inc (NASDAQ:PCRX) released its quarterly earnings results on Thursday, August, 8th. The company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.14 by $0.27. The company had revenue of $102.60 million for the quarter, compared to analyst estimates of $99.92 million. Pacira Biosciences had a return on equity of 8.62% and a net margin of 2.04%. Pacira Biosciences's quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.24 EPS. View Pacira Biosciences' Earnings History.
When is Pacira Biosciences' next earnings date?
What guidance has Pacira Biosciences issued on next quarter's earnings?
Pacira Biosciences issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $408-420 million, compared to the consensus revenue estimate of $415.63 million.
What price target have analysts set for PCRX?
16 brokers have issued 1-year price objectives for Pacira Biosciences' shares. Their forecasts range from $38.00 to $85.00. On average, they expect Pacira Biosciences' stock price to reach $54.6429 in the next twelve months. This suggests a possible upside of 47.0% from the stock's current price. View Analyst Price Targets for Pacira Biosciences.
What is the consensus analysts' recommendation for Pacira Biosciences?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 1 sell rating, 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacira Biosciences.
What are Wall Street analysts saying about Pacira Biosciences stock?
Here are some recent quotes from research analysts about Pacira Biosciences stock:
- 1. According to Zacks Investment Research, "Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience in April 2019. Pacira’s top line mainly comprises contribution from its marketed drug Exparel. The company’s efforts to expand Exparel's label are encouraging. In April 2018, the FDA approved Exparel's label expansion to include administration via nerve block for prolonged regional analgesia. This is a positive for the company as it will further boost sales of Exparel. Pacira’s agreement with Nuance for the development/commercialization of Exparel in China is also an upside. Shares of the company have underperformed the industry year to date. The company remains heavily dependent on Exparel for growth, any setback for the drug will severely hurt the stock in the long run." (8/2/2019)
- 2. Stifel Nicolaus analysts commented, "We are upgrading shares of PCRX to Hold as we believe the near-term competitive threat from HRTX’s HTX-011 will be less of a factor over the next 12 months and the recent strength in the stock indicates to us that the stock is fairly valued at these levels. While PCRX’s Exparel revenues came in a little shy of 1Q19 consensus, we believe the recent price increase on Exparel, the lack of a competitive entry from HRTX and the favorable reimbursement scheme in the ASC setting should allow PCRX to achieve its 2019 Exparel guidance, in our view. Our revised 2019 Exparel estimates are now at the midpoint of management’s guidance of ~$400-$410 million (vs. consensus of ~$403 million). Additionally, we incorporate PCRX’s recent acquisition, Iovera, into our model and raise our target price to $45 a share." (5/2/2019)
- 3. Mizuho analysts commented, "We valued Pacira based on an equally weighted blend of discounted cash flow analysis and sum-of-the-parts valuation. This analysis generates our $43 price target, supporting our Neutral rating." (11/1/2018)
Has Pacira Biosciences been receiving favorable news coverage?
News headlines about PCRX stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pacira Biosciences earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Pacira Biosciences.
Who are some of Pacira Biosciences' key competitors?
Some companies that are related to Pacira Biosciences include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Allakos (ALLK), Nektar Therapeutics (NKTR), FibroGen (FGEN), Evotec (EVTCY), Alkermes (ALKS) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Pacira Biosciences own?
Who are Pacira Biosciences' key executives?
Pacira Biosciences' management team includes the folowing people:
- Mr. David M. Stack, Chairman & CEO (Age 69)
- Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 58)
- Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)
- Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 52)
- Mr. Dennis McLoughlin, Chief Commercial Officer (Age 53)
Who are Pacira Biosciences' major shareholders?
Pacira Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.52%), D. E. Shaw & Co. Inc. (3.00%), Stephens Investment Management Group LLC (2.93%), Point72 Asset Management L.P. (2.80%), Renaissance Technologies LLC (2.64%) and Baillie Gifford & Co. (2.41%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Gary W Pace, James B Jones, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Richard Scranton. View Institutional Ownership Trends for Pacira Biosciences.
Which major investors are selling Pacira Biosciences stock?
PCRX stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Russell Investments Group Ltd., Prudential Financial Inc., First Trust Advisors LP, Bank of Montreal Can, Laurion Capital Management LP, Public Employees Retirement System of Ohio and Rice Hall James & Associates LLC. Company insiders that have sold Pacira Biosciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Biosciences.
Which major investors are buying Pacira Biosciences stock?
PCRX stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Paulson & CO. Inc., Point72 Asset Management L.P., D. E. Shaw & Co. Inc., Tamarack Advisers LP, Gagnon Securities LLC, Balyasny Asset Management LLC and JPMorgan Chase & Co.. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace and Mark A Kronenfeld. View Insider Buying and Selling for Pacira Biosciences.
How do I buy shares of Pacira Biosciences?
Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pacira Biosciences' stock price today?
One share of PCRX stock can currently be purchased for approximately $37.16.
How big of a company is Pacira Biosciences?
Pacira Biosciences has a market capitalization of $1.55 billion and generates $337.28 million in revenue each year. The company earns $-470,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.View Additional Information About Pacira Biosciences.
What is Pacira Biosciences' official website?
How can I contact Pacira Biosciences?
Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]
MarketBeat Community Rating for Pacira Biosciences (NASDAQ PCRX)
MarketBeat's community ratings are surveys of what our community members think about Pacira Biosciences and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
